
Merodis executed the sale of ImmuneHealth's activities to Caprion Biosciences.

Brussels, Belgium, September 15, 2016

Merodis, is proud to announce that it advised ImmuneHealth for the sale of its immuno-monitoring activities to Caprion Biosciences.

ImmuneHealth (<http://www.immunehealth.eu/>), founded in 2007 by the initiative of ULB and GSK, is a biomarker CRO specialized in human biospecimen procurement, immuno-monitoring readouts for clinical trials and biomarkers immune-testing in the field of vaccines, immunotherapies, cell therapies and diagnostic. The Gosselies-based CRO built a reputable position in cellular and humoral immunity analytical services for biotech and pharma clients over the years. The company has transferred all its immune-monitoring activities and assets to Caprion which intends to develop its immune-monitoring activity in Belgium and in Europe thanks to this investment.

Caprion (<http://www.caprion.com/en/corporate/>), is a leading Canadian global provider of specialized immunology and proteomics analytical laboratory services to pharmaceutical and biotechnology companies. The company has been recently acquired by GHO capital, a UK-based specialized healthcare private equity fund. This transaction is part of Caprion's strategic priorities to create, develop and expand its business in Europe from operations in Belgium. Caprion has expressed the willingness to develop its activities from the Biopark of Gosselies..

For more information, please contact:

Thierry Hazevoets, tha@merodis.com, +32 495 58 68 98.

Gabriel de Launoit, gdl@merodis.com, +32 496 10 89 20.

About Merodis

Part of the euroMerger international network, Merodis provides middle-market companies with a wide range of financial advisory services in support of mergers, acquisitions, divestitures, capital raising and corporate restructuring. For detailed information concerning the range of services offered, recent transactions and credentials, please consult www.merodis.com.

If you no longer wish to receive this information, please send an email with subject "Unsubscribe" to info@merodis.com. If you want to be informed on new investment opportunities or get the latest news about Merodis, please click <http://www.merodis.com/contact.php?l2=1>